BioMérieux Acquires Accellix to Enhance Quality Control in Advanced Therapies

bioMérieux has announced the acquisition of Accellix, a US-based company specializing in rapid flow cytometry solutions for cell and gene therapy. This acquisition aims to strengthen bioMérieux’s Pharmaceutical Quality Control division and enhance patient outcomes globally by investing in innovative technologies. Accellix provides a platform that delivers fast results, which is crucial for maintaining quality during the manufacturing of cell therapies.

Cell and gene therapies are at the forefront of medical treatment, promising to address previously untreatable conditions. However, maintaining their quality and reliability is vital for success. Clinical analyses indicate that these therapies have significantly higher success rates compared to traditional treatments. Accellix's platform allows for streamlined quality control, catering to regulatory demands and expediting patient access to advanced therapies.

bioMérieux's acquisition, costing approximately €35 million, follows a collaboration that began in 2020. This move is set to expand bioMérieux’s quality control solutions portfolio, covering raw materials, in-process testing, and product efficacy and safety. By joining forces with Accellix, bioMérieux seeks to lead global innovation in advanced therapy quality control, facilitating scalable and automated solutions for the pharmaceutical industry.